Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development

Table 3

Associations between MPNs and cytokines.

Inflammatory marker	Impact	Disorder
B2MICG	Symptoms	MF
BMP1	Disease advancement	PMF
BMP6	Disease advancement	PMF
BMP7	Disease advancement	PMF
BMP-Rcp2	Disease advancement	PMF
CD40L	Loss of appetite	MF
CRP	Thrombosis; atherogenesis	PV, ET
Ferritin	Pruritus	MF
FGF	Marrow fibrosis	PV, ET, PMF
HGF	Splenomegaly	PMF
IFN	Associated with JAK2V617F	MF
IL-12	Inferior survival; transfusion requirements, vascular complications	MF
IL-15	Inferior survival	MF
IL-17A	Associated with JAK2V617F	MF
IL-1B	Associated with JAK2V617F	MF
IL-1RA	Splenomegaly	PMF
IL-2R	Inferior survival; transfusion requirements	MF
IL-8	Elevated blasts; constitutional symptoms	MF
IL-8	Associated with JAK2V617F	MF
IP-10	Inferior survival	MF
LEPTIN	Symptoms; weight loss	MF
MIG	Splenomegaly	PMF
PAL1	Insomnia	MF
PTX	Thrombosis; atherogenesis	PV, ET
RANTES	Insomnia	MF
TIMP1	Symptoms	MF
TNF-1	Clonal expansion	JAK2V617F+ MPNs
TNFRII	Symptoms	MF
VCAM1	Symptoms	MF
VEGFb	Marrow fibrosis	PV, ET, PMF

ET: essential thrombocythemia; MF: myelofibrosis; MPN: myeloproliferative neoplasm; PMF: primary myelofibrosis; PV: primary myelofibrosis.
Refer to Table 2 for definition.